Diarrhea News and Research

Latest Diarrhea News and Research

AMAG receives Health Canada Notice of Non-Compliance for Feraheme NDS

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that it has received a Notice of Non-Compliance (NON) from Health Canada regarding its New Drug Submission (NDS) for Feraheme® (ferumoxytol) injection for intravenous (IV) use for the treatment of iron deficiency anemia in adult chronic kidney disease patients.

9 Feb 2011

Abbott's Ibis, PLEX-ID technologies identify causative organism of plague in Afghanistan

Today, at the American Society for Microbiology Conference on Biodefense and Emerging Diseases, scientists from Abbott Molecular presented data showing the unique power of the company's Ibis technology to identify and further characterize unknown disease-causing pathogens to help aid in the bioforensic analysis of pandemic outbreaks.

8 Feb 2011

Genentech's OCEANS Phase III study of Avastin in platinum-sensitive ovarian cancer meets primary endpoint

Genentech, a member of the Roche Group, announced today that OCEANS, a Phase III study evaluating Avastin® (bevacizumab) in combination with chemotherapy (carboplatin and gemcitabine) followed by continued use of Avastin alone until disease progression in women with previously treated (recurrent), platinum-sensitive ovarian cancer, met its primary endpoint.

8 Feb 2011

New study shows economic burden of dengue in Western Hemisphere is $2.1 billion per year

Dengue illness, the most common mosquito-borne viral disease in the world, has expanded from its Southeast Asian origins and is resurgent in countries such as Argentina, Chile and the continental United States.

8 Feb 2011

Progenics, Salix enter exclusive worldwide license agreement for RELISTOR

Progenics Pharmaceuticals, Inc. and Salix Pharmaceuticals, Ltd. today announced that they have entered into an exclusive worldwide (except Japan) agreement by which Salix has licensed rights to RELISTOR® (methylnaltrexone bromide).

7 Feb 2011

FDA approves Makena injection to reduce risk of preterm delivery

The U.S. Food and Drug Administration today approved Makena (hydroxyprogesterone caproate) injection to reduce the risk of preterm delivery before 37 weeks of pregnancy, in pregnant women with a history of at least one spontaneous preterm birth.

5 Feb 2011

Patients receiving cancer treatment may experience skin, hair, nail problems

A cancer diagnosis and subsequent treatment, which commonly includes chemotherapy or radiation, can be taxing physically and emotionally on any patient. If that is not enough, dermatologists are cautioning patients receiving cancer treatment and cancer survivors that they may experience a host of skin, hair or nail problems as a direct result of their therapy that may require additional treatment by a dermatologist.

5 Feb 2011

Phase II results of VELCADE in patients with aggressive lymphoma published in Journal of Clinical Oncology

Millennium: The Takeda Oncology Company today announced that Phase II results of a clinical trial examining VELCADE (bortezomib) in patients with previously untreated aggressive lymphoma were published in the Journal of Clinical Oncology.

5 Feb 2011

Study finds total cost of dengue illness in Americans to be $2.1 billion per annum

The first assessment of the total cost of dengue illness in the Americas reveals the economic burden to be approximately $2.1 billion per year, exceeding that from other viral illnesses including human papillomavirus and rotavirus.

4 Feb 2011

New England Journal publishes fidaxomicin Phase 3 trial results against CDI

Optimer Pharmaceuticals, announced The New England Journal of Medicine has published results from the North American Phase 3 trial evaluating the safety and efficacy of the Company's novel antibiotic fidaxomicin as a treatment for patients with Clostridium difficile infection.

3 Feb 2011

Shionogi-ViiV Healthcare initiates 572-Trii fixed-dose combination therapy study for HIV

Shionogi-ViiV Healthcare, LLC announced today that the first patient has entered the clinical study, SINGLE (ING114467), designed to support a new fixed-dose combination (FDC) therapy for the treatment of HIV.

3 Feb 2011

Enrollment stopped in one of two global necitumumab Phase III studies in NSCLC

Eli Lilly and Company and Bristol-Myers Squibb Company announced today that they have stopped enrollment in one of their two global Phase III studies evaluating necitumumab, an investigational anti-cancer agent, as a first-line treatment for advanced non-small cell lung cancer (NSCLC).

3 Feb 2011

CDH first hospital in New England to use Xenex PX-UV disinfection system

Cooley Dickinson Hospital (CDH) today announced it is the first hospital in New England to use the Xenex PX-UV disinfection system to disinfect its patient and operating rooms.

2 Feb 2011

AVEO commences enrollment in tivozanib Phase 2 study in renal cell carcinoma

AVEO Pharmaceuticals, Inc. today announced that it has initiated patient enrollment in a multi-center Phase 2 exploratory biomarker study of tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with renal cell carcinoma (RCC).

1 Feb 2011

Silicon dioxide coated rust nanoparticles to fight cervical cancer

The next big thing in medical diagnostics could be minutes particles of rust, iron oxide, coated with the material from which sand is formed, silicon dioxide. These magnetic nanoparticles, a mere 29 to 230 nanometers across, can be used to trap antibodies to the virus that causes cervical cancer and to the bacteria that causes potentially lethal diarrhea.

1 Feb 2011

U.K., Gates Foundation announce extra funding for global polio eradication as WEF wraps up

U.K. Prime Minister David Cameron and Bill Gates, co-chair of the Bill & Melinda Gates Foundation, on Friday at the World Economic Forum (WEF) in Davos, Switzerland, announced "extra financing for polio eradication, easing a shortfall in funding that hinders a global effort to stop the crippling virus," Bloomberg reports.

1 Feb 2011

AVANIR's NUEDEXTA for pseudobulbar affect now available by prescription

AVANIR Pharmaceuticals, Inc. today announced that NUEDEXTA™ (dextromethorphan hydrobromide and quinidine sulfate) is now available by prescription in the United States. NUEDEXTA is the first and only treatment approved by the U.S. Food and Drug Administration (FDA) for pseudobulbar affect (PBA).

1 Feb 2011

Baxter launches OLIMEL emulsion for parenteral nutrition

Baxter International today announced the launch of OLIMEL emulsion for infusion in Canada at the American Society of Parenteral and Enteral Nutrition's Clinical Nutrition Week.

From Baxter International Inc. 31 Jan 2011

GATTEX Phase 3 pivotal study reaches primary efficacy endpoint of reducing PN in patients with SBS

NPS Pharmaceuticals, a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced that its Phase 3 pivotal study of GATTEX met the primary efficacy endpoint of reducing parenteral nutrition dependence in patients with adult short bowel syndrome.

31 Jan 2011

Phase III study shows tapentadol ER relieves chronic pain associated with DPN

New research has been published indicating that patients suffering from a painful complication of diabetes may experience a significant improvement in their pain as measured by a pain intensity scale when using an investigational pain medication.

29 Jan 2011

Diarrhea News and Research

Latest Diarrhea News and Research

AMAG receives Health Canada Notice of Non-Compliance for Feraheme NDS

Abbott's Ibis, PLEX-ID technologies identify causative organism of plague in Afghanistan

Genentech's OCEANS Phase III study of Avastin in platinum-sensitive ovarian cancer meets primary endpoint

New study shows economic burden of dengue in Western Hemisphere is $2.1 billion per year

Progenics, Salix enter exclusive worldwide license agreement for RELISTOR

FDA approves Makena injection to reduce risk of preterm delivery

Patients receiving cancer treatment may experience skin, hair, nail problems

Phase II results of VELCADE in patients with aggressive lymphoma published in Journal of Clinical Oncology

Study finds total cost of dengue illness in Americans to be $2.1 billion per annum

New England Journal publishes fidaxomicin Phase 3 trial results against CDI

Shionogi-ViiV Healthcare initiates 572-Trii fixed-dose combination therapy study for HIV

Enrollment stopped in one of two global necitumumab Phase III studies in NSCLC

CDH first hospital in New England to use Xenex PX-UV disinfection system

AVEO commences enrollment in tivozanib Phase 2 study in renal cell carcinoma

Silicon dioxide coated rust nanoparticles to fight cervical cancer

U.K., Gates Foundation announce extra funding for global polio eradication as WEF wraps up

AVANIR's NUEDEXTA for pseudobulbar affect now available by prescription

Baxter launches OLIMEL emulsion for parenteral nutrition

GATTEX Phase 3 pivotal study reaches primary efficacy endpoint of reducing PN in patients with SBS

Phase III study shows tapentadol ER relieves chronic pain associated with DPN

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Diarrhea News and Research

Latest Diarrhea News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in